PTHrP stimulates prostate cancer cell growth and upregulates aldo-keto reductase 1C3.

The aim of the study was to demonstrate the role of parathyroid hormone related protein (PTHrP) in stimulating aldo-keto reductase (AKR) 1C3 expression in prostate cancer (CaP) cells. CaP cell proliferation and resistance to apoptosis was increased by PTHrP transfection. Conversely, reducing AKR1C3 expression by siRNA decreased cell proliferation. Since these effects could be mediated through AKR1C3-catalyzed reductions of the PPARγ ligand, 15-DeoxyΔ(12,14)-PGJ(2), we treated the cells with prostaglandins (PG). (PG) D(2) inhibited cell proliferation, but its metabolite, 9α,11β-PGF(2), did not effect CaP cell growth. The AKR1C family members serve as potential therapeutic targets for CaP therapy.

[1]  F. Stanczyk,et al.  Selective reduction of AKR1C2 in prostate cancer and its role in DHT metabolism , 2003, The Prostate.

[2]  F. Stanczyk,et al.  Selective Loss of AKR1C1 and AKR1C2 in Breast Cancer and Their Potential Effect on Progesterone Signaling , 2004, Cancer Research.

[3]  Robert A Newman,et al.  Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. , 2005, Cancer research.

[4]  S. Rudnick,et al.  Development of Nonsteroidal Anti-Inflammatory Drug Analogs and Steroid Carboxylates Selective for Human Aldo-Keto Reductase Isoforms: Potential Antineoplastic Agents That Work Independently of Cyclooxygenase Isozymes , 2005, Molecular Pharmacology.

[5]  Seon-Hwa Lee,et al.  Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer , 2010, The Journal of Steroid Biochemistry and Molecular Biology.

[6]  C. Korch,et al.  Molecular characterization of human prostate carcinoma cell lines , 2003, The Prostate.

[7]  W. Wachsman,et al.  Parathyroid hormone-like protein: alternative messenger RNA splicing pathways in human cancer cell lines. , 1994, Cancer research.

[8]  M. Lewis,et al.  Comparative anatomy of the aldo-keto reductase superfamily. , 1997, The Biochemical journal.

[9]  M. Robbins,et al.  Peroxisome proliferator-activated receptor- gamma expression in human malignant and normal brain, breast and prostate-derived cells. , 2001, Prostaglandins, leukotrienes, and essential fatty acids.

[10]  A. Gazdar,et al.  All major lung cancer cell types produce parathyroid hormone-like protein: heterogeneity assessed by high performance liquid chromatography. , 1991, Endocrinology.

[11]  M. Falzon,et al.  Parathyroid hormone-related protein enhances PC-3 prostate cancer cell growth via both autocrine/paracrine and intracrine pathways , 2002, Regulatory Peptides.

[12]  Robert M Hoffman,et al.  Direct evidence that PTHrP expression promotes prostate cancer progression in bone. , 2005, Biochemical and biophysical research communications.

[13]  Hsueh-Kung Lin,et al.  Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. , 2006, Endocrine-related cancer.

[14]  S. Parsons,et al.  The neuroendocrine-derived peptide parathyroid hormone-related protein promotes prostate cancer cell growth by stabilizing the androgen receptor. , 2009, Cancer research.

[15]  L. Deftos,et al.  Parathyroid hormone-related protein ameliorates death receptor-mediated apoptosis in lung cancer cells. , 2003, American journal of physiology. Cell physiology.

[16]  Michael E. Burczynski,et al.  Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1–AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones , 2000 .

[17]  Trevor M Penning,et al.  Steroid Hormone Transforming Aldo‐Keto Reductases and Cancer , 2009, Annals of the New York Academy of Sciences.

[18]  J. Dulińska,et al.  Does the inhibition of c-myc expression mediate the anti-tumor activity of PPAR's ligands in prostate cancer cell lines? , 2007, Archives of biochemistry and biophysics.

[19]  T. Penning,et al.  Structure–function of human 3α-hydroxysteroid dehydrogenases: genes and proteins , 2004, Molecular and Cellular Endocrinology.

[20]  L. Deftos,et al.  Elimination of the carboxy-terminal sequences of parathyroid hormone-related protein 1-173 increases production and secretion of the truncated forms. , 1996, Endocrinology.

[21]  D. Tindall,et al.  Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor γ ligand, 15-deoxy-Δ12,14-prostaglandin J2 , 2000 .

[22]  S. Yasothornsrikul,et al.  Proteolysis of ProPTHrP(1-141) by "prohormone thiol protease" at multibasic residues generates PTHrP-related peptides: implications for PTHrP peptide production in lung cancer cells. , 2001, Biochemical and biophysical research communications.

[23]  T. Golub,et al.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. , 2006, Cancer research.

[24]  I. Tsigelny,et al.  Coherent Expression Chromosome Cluster Analysis Reveals Differential Regulatory Functions of Amino-Terminal and Distal Parathyroid Hormone-Related Protein Domains in Prostate Carcinoma , 2005, Journal of biomedicine & biotechnology.

[25]  Donna M. Peehl,et al.  Aldo-keto reductase (AKR) 1C3: Role in prostate disease and the development of specific inhibitors , 2006, Molecular and Cellular Endocrinology.

[26]  S. Culine,et al.  [Role of PPARgamma in the control of prostate cancer growth: a new approach for therapy]. , 2007, Bulletin du cancer.

[27]  G. Strewler.  The physiology of parathyroid hormone-related protein. , 2000, The New England journal of medicine.

[28]  D. Harrison,et al.  Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members. , 1999, The Biochemical journal.

[29]  H. Jüppner,et al.  Parathyroid hormone and parathyroid hormone-related peptide, and their receptors. , 2005, Biochemical and biophysical research communications.

[30]  R. Hayden,et al.  The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs. , 2003, Cancer research.

[31]  S. Rabbani,et al.  Over‐production of parathyroid hormone–related peptide results in increased osteolytic skeletal metastasis by prostate cancer cells In vivo , 1999, International journal of cancer.